Compare Mondaycom Ltd (MNDY) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mondaycom Ltd vs Spyre Therapeutics Inc. Common Stock — how do they compare? Mondaycom Ltd trades at $87.2 (market cap $3.57B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 2.1× Mondaycom Ltd's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mondaycom Ltd for 16 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MNDY | SYRE | |
|---|---|---|
Market Cap | $3.57B | $7.52B |
Volume | 1,023,013 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $205.24 | $108.92 |
52-Week Low | $58.81 | $22.18 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $2.74B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monday.com (MNDY) trades at $84.69, showing minimal daily movement (-0.08%) with neutral technical signals. The company demonstrates strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust revenue growth from $1.23B to $1.4B. Recent news highlights AI integration at Elevate '26 conference and inclusion in multiple growth stock lists, while technical indicators show mixed signals with RSI at neutral levels and key support at $83.
The stock presents a compelling growth story with 61.5% analyst buy ratings and a $108.64 consensus target offering 28% upside. However, elevated valuation multiples (P/E 35.83, EV/EBITDA 50.12) and competitive pressures from Meta's enterprise software push pose risks. Net cash flow turned negative in 2026 (-$737M) despite strong operating performance, requiring monitoring of capital allocation.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
